Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3137]

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

The placebo effect in oncology trials and the criteria for approving drugs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )

Comment: POLAR gene profile can identify which patients can safely avoid...

Prof Christos Markopoulos- National and Kapodistrian University of Athens...

Updates from TAILORx and RxPONDER: Implications for practice

Prof Christos Markopoulos and Dr Kevin Kalinsky

Updates from TAILORx and RxPONDER: Implications for practice ( Prof Christos Markopoulos and Dr Kevin Kalinsky )

Interruption of endocrine therapy in young breast cancer patients does not...

Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse ( Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA )

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...

Dr Monzr Al Malki - City of Hope, Duarte, USA

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease ( Dr Monzr Al Malki - City of Hope, Duarte, USA )

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA

Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )

More from ecancer